Meeder Asset Management Inc. Has $47,000 Holdings in OraSure Technologies, Inc. (NASDAQ:OSUR)
Meeder Asset Management Inc. increased its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 908.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,284 shares of the medical instruments supplier’s stock after acquiring an additional 3,859 shares during the period. Meeder Asset Management Inc.’s holdings in OraSure Technologies were worth $47,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of OSUR. First Trust Advisors LP acquired a new stake in shares of OraSure Technologies in the 1st quarter valued at about $353,000. Rhumbline Advisers grew its holdings in shares of OraSure Technologies by 5.4% during the fourth quarter. Rhumbline Advisers now owns 210,520 shares of the medical instruments supplier’s stock worth $1,690,000 after buying an additional 10,753 shares in the last quarter. Swiss National Bank raised its position in OraSure Technologies by 1.6% in the 4th quarter. Swiss National Bank now owns 118,200 shares of the medical instruments supplier’s stock valued at $949,000 after buying an additional 1,900 shares during the last quarter. State Street Corp lifted its stake in OraSure Technologies by 2.9% in the 4th quarter. State Street Corp now owns 2,572,896 shares of the medical instruments supplier’s stock valued at $20,660,000 after acquiring an additional 72,814 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its position in OraSure Technologies by 36.5% during the 4th quarter. Victory Capital Management Inc. now owns 13,114 shares of the medical instruments supplier’s stock worth $105,000 after acquiring an additional 3,505 shares during the last quarter. 90.07% of the stock is currently owned by institutional investors and hedge funds.
OSUR has been the subject of several recent research reports. ValuEngine cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Friday, May 1st. BidaskClub raised OraSure Technologies from a “sell” rating to a “hold” rating in a research report on Saturday. Stephens began coverage on OraSure Technologies in a research report on Tuesday, April 21st. They set an “equal weight” rating and a $14.00 price target for the company. Zacks Investment Research upgraded OraSure Technologies from a “hold” rating to a “strong-buy” rating and set a $18.00 price target for the company in a research note on Wednesday, May 6th. Finally, Lake Street Capital started coverage on OraSure Technologies in a research note on Thursday. They set a “buy” rating and a $19.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $14.75.
OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.06). OraSure Technologies had a net margin of 8.06% and a return on equity of 1.69%. The business had revenue of $31.60 million during the quarter, compared to analyst estimates of $29.48 million. During the same period in the previous year, the business earned ($0.05) earnings per share. The business’s quarterly revenue was up 4.9% on a year-over-year basis. As a group, equities analysts forecast that OraSure Technologies, Inc. will post -0.19 earnings per share for the current year.
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Recommended Story: Why is cost of goods sold important?
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.